ArjunVasantBalarMD

Genitourinary Oncology, Hematologic Oncology

Associate Professor, Medicine, New York University School of Medicine; Director - Genitourinary Medical Oncology Program, Perlmutter Cancer Center at NYU Langone Health

Join to view full profile

Dr. Balar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Balar's full profile

Already have an account?

Office
160 East 34th Street
10th Floor
New York, NY 10016
Phone+1 212-731-5820

Fax+1 212-731-5527
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2006 - 2009
University of South Florida College of MedicineClass of 2006

Certifications & Licensure

NY State Medical License 2008 - 2023

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 2
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
MRI and Bladder Cancer Chemotherapy Start of enrollment: 2013 Aug 01
Withdrawn
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder Start of enrollment: 2016 Aug 11
Active, not recruiting
Phase 2
Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer Start of enrollment: 2017 Sep 13
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

HSR24-138: Real-World Treatment (tx) Patterns and Outcomes for First-Line (1L) Novel Hormonal Agent (NHA) Naïve Metastatic Castration Resistant Prostate Cancer (mCRPC)...
Emily Nash Smyth, Samuel Whipple, Mark Guinter, Nadine Haddad, Wenxian Piao, Zhanglin Cui, Arjun Balar> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
Neeraj Agarwal, Daniel Castellano, Teresa Alonso-Gordoa, Jose Angel Arranz Arija, Emeline Colomba, Gwenaelle Gravis, Loic Mourey, Stephane Oudard, Aude Fléchon, Macare...> ;Clinical Cancer Research. 2024 Mar 21
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
David R Wise, Russell K Pachynski, Samuel R Denmeade, Rahul R Aggarwal, Jiehui Deng, Victor Adorno Febles, Arjun V Balar, Minas P Economides, Cynthia Loomis, Shanmugap...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 10
1 citations
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Nobuaki Matsubara, Ronald de Wit, Arjun Vasant Balar, Arlene O Siefker-Radtke, Jakub Zolnierek, Tibor Csoszi, Sang Joon Shin, Se Hoon Park, Vagif Atduev, Mahmut Gumus,...> ;European Urology. 2024 Mar 1
2 citations
Single-cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile.
Victor R Adorno Febles, Yuan Hao, Aarif Ahsan, Jiansheng Wu, Yingzhi Qian, Hua Zhong, Stacy Loeb, Danil V Makarov, Herbert Lepor, James Wysock, Samir S Taneja, William...> ;The Prostate. 2023 Jun 1
2 citations
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
James Larkin, Mototsugu Oya, Marcella Martignoni, Fiona Thistlethwaite, Paul Nathan, Moshe C Ornstein, Thomas Powles, Kathryn E Beckermann, Arjun V Balar, David McDerm...> ;The Oncologist. 2023 Apr 6
21 citations
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
A V Balar, D E Castellano, P Grivas, D J Vaughn, T Powles, J Vuky, Y Fradet, J-L Lee, L Fong, N J Vogelzang, M A Climent, A Necchi, D P Petrylak, E R Plimack, J Z Xu, ...> ;Annals of Oncology. 2023 Mar 1
5 citations
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02.
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal...> ;European Urology. 2022 Oct 1
16 citations
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A Climent, Daniel P Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N Sternberg, Peter H O'Donnell, Tho...> ;Clinical Cancer Research. 2022 May 13
11 citations
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibito...
Bradley McGregor, Peter H O'Donnell, Arjun Balar, Daniel Petrylak, Jonathan Rosenberg, Evan Y Yu, David I Quinn, Elisabeth I Heath, Mary Campbell, Zsolt Hepp, Caroline...> ;European Urology. 2022 May 1
25 citations
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Samuel A Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan, Min Yuen Teo, Chung-Han Lee, David Aggen, Danielle Zimmerman, Deaglan McHugh, Arl...> ;Journal of Clinical Oncology. 2022 Apr 20
11 citations
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.
Nizar M Tannir, Daniel C Cho, Adi Diab, Mario Sznol, Mehmet A Bilen, Arjun V Balar, Giovanni Grignani, Erika Puente, Lily Tang, David Chien, Ute Hoch, Arkopal Choudhur...> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
3 citations
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prosta...
Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath,...> ;European Urology Open Science. 2021 Dec 1
1 citations
Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States
Jennifer Wu, Amin Yakubov, Maher Abdul-Hay, Erica Love, Gianna Kroening, Deirdre Jill Cohen, Christy Spalink, Ankeeta Joshi, Arjun Vasant Balar, Kathie-Ann Joseph, Jos...> ;JCO Oncology Practice. 2021 Nov 8
12 citations
Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.
Brian W. Labadie, Arjun Vasant Balar, Jason J. Luke> ;Cancers. 2021 Oct 28
1 citations
Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply
Arjun Vasant Balar, Ashish M. Kamat, Ronald de Wit, Keynote investigators> ;The Lancet. Oncology. 2021 Sep 1
17 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer.
Matthew D. Galsky, Arjun Vasant Balar, Peter C. Black, Matthew T. Campbell, Gail S Dykstra, Petros Grivas, Shilpa Gupta, Christoper J Hoimes, Lidia P Lopez, Joshua J. ...> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
99 citations
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Evan Y. Yu, Daniel P. Petrylak, Peter H. O'Donnell, Jae-Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. ...> ;The Lancet. Oncology. 2021 Jun 1
190 citations
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, ...
Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni, Edward Uchio, Joost L. Boormans, Mathieu Roumiguié, Laurence Eliot Miles Krieger, Eric A. Singer, Dean F. Bajo...> ;The Lancet. Oncology. 2021 Jul 1
4 citations
Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival.
Guilhem Richard, Anne S. De Groot, Gary D. Steinberg, Tzintzuni Garcia, Alec Kacew, Matthew Ardito, William D. Martin, Gad Berdugo, Michael F. Princiotta, Arjun Vasant...> ;Scientific Reports. 2021 May 11
48 citations
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Thomas Powles, Danielle Carroll, Simon Chowdhury, Gwenaelle Gravis, Florence Joly, Joan Carles, Aude Flechon, Pablo Maroto, Daniel P. Petrylak, Frederic Rolland, Natal...> ;Nature Medicine. 2021 May 3
196 citations
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Ch...
Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Flechon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philip...> ;Journal of Clinical Oncology. 2021 Apr 30
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced an...
Min Yuen Teo, Jose Mauricio Mota, Karissa Whiting, Han A. Li, Samuel A. Funt, Chung-Han Lee, David B. Solit, Hikmat Al-Ahmadie, Matthew I. Milowsky, Arjun Vasant Balar...> ;European Urology. 2021 Feb 9
5 citations
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Robert Huddart, Arlene O. Siefker-Radtke, Arjun Vasant Balar, Mehmet Asim Bilen, Thomas Powles, Aristotelis Bamias, Daniel Castellano, Maged F. Khalil, Michiel S. van ...> ;Future Oncology. 2021 Jan 1
27 citations
Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA.
Saranya Akumalla, Russell Madison, Douglas I. Lin, Alexa B. Schrock, Evgeny Yakirevich, Margaret Rosenzweig, Arjun Vasant Balar, Garrett M. Frampton, Claire Edgerly, R...> ;Oncology. 2020 Sep 23
Join now to see all

Lectures

Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 stu...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Targeted Oncology - FDA Cracks down on Dangling Accelerated Approvals in 2021, Pathway Is ScrutinizedDecember 20th, 2021
Treatment Considerations for Upper Tract Urothelial Carcinoma - Eugene Pietzak and Arjun BalarJune 16th, 2021
$Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun Balar$
Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Bladder Cancer - Arjun BalarJune 10th, 2021
Join now to see all